{"entity":{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","aka":["Vall d’Hebron Barcelona Hospital Campus","Vall d'Hebron Barcelona Hospital Campus"],"tldr":"Vall d'Hebron is Spain's leading cancer research hospital and a global leader in phase 1 and breast cancer ADC trials.","summary":"Vall d'Hebron University Hospital and its research arm VHIO in Barcelona are Spain's leading cancer research centre and rank twenty-eighth in the Newsweek/Statista oncology list. Under Tabernero and Javier Cortés it has led DESTINY-Breast03 and DESTINY-Breast09, the TROPION-Breast programme, and the BEACON and BREAKWATER colorectal trials that established encorafenib in BRAF V600E-mutated disease, and it runs one of Europe's largest phase 1 units, with Elena Garralda, Cristina Saura, Enriqueta Felip and Elena Élez also listed. OnCo links it to the MYC and TGF-beta pathways, to the SOLTI and CNIO networks, and to ideas on drugging MYC directly and on hospital-exemption cell therapies. Keeping academic independence while leading so many company trials is the standing question. Its breast ADC and colorectal programmes are the ones to read.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://vhio.net"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["encorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["destiny-breast03","destiny-breast09"],"people":["elena-garralda","cristina-saura","elena-elez","enriqueta-felip","javier-cortes","joaquin-arribas","josep-tabernero","albert-salazar-soler"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Barcelona","country":"ES","lat":41.427,"lng":2.141,"institutionType":"cancer-center","website":"https://vhio.net","newsweekOncology2026":28,"programs":["Breast ADC trials (Cortés)","Colorectal (Tabernero)","Phase 1"]},"route":"/institutions/vall-dhebron/","neighbours":{"drug":[{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"}],"trial":[{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/"},{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/"},{"id":"winther","kind":"trial","name":"WINTHER","route":"/trials/winther/"}],"person":[{"id":"albert-salazar-soler","kind":"person","name":"Albert Salazar Soler","route":"/people/albert-salazar-soler/"},{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/"},{"id":"cristina-saura","kind":"person","name":"Cristina Saura","route":"/people/cristina-saura/"},{"id":"elena-elez","kind":"person","name":"Elena Élez","route":"/people/elena-elez/"},{"id":"elena-garralda","kind":"person","name":"Elena Garralda","route":"/people/elena-garralda/"},{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/"},{"id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/"},{"id":"joaquin-arribas","kind":"person","name":"Joaquín Arribas","route":"/people/joaquin-arribas/"},{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/"}],"idea":[{"id":"idea-drugging-myc","kind":"idea","name":"Can MYC be drugged directly, and will patients tolerate it?","route":"/ideas/idea-drugging-myc/"},{"id":"idea-fund-hospital-exemption-registry","kind":"idea","name":"Hospital-exemption cell therapies at scale, backed by a shared registry","route":"/ideas/idea-fund-hospital-exemption-registry/"}],"pathway":[{"id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/"},{"id":"tgf-beta","kind":"pathway","name":"TGF-β signalling","route":"/pathways/tgf-beta/"}],"paper":[{"id":"paper-breakwater-nejm-2025","kind":"paper","name":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-breakwater-nejm-2025/"}],"institution":[{"id":"cnio","kind":"institution","name":"Centro Nacional de Investigaciones Oncológicas (CNIO)","route":"/institutions/cnio/"},{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/"},{"id":"hospital-de-sant-pau","kind":"institution","name":"Hospital de la Santa Creu i Sant Pau","route":"/institutions/hospital-de-sant-pau/"},{"id":"hospital-del-mar","kind":"institution","name":"Hospital del Mar / Hospital del Mar Research Institute","route":"/institutions/hospital-del-mar/"},{"id":"hospital-sant-joan-de-reus","kind":"institution","name":"Hospital Universitari Sant Joan de Reus","route":"/institutions/hospital-sant-joan-de-reus/"},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/"}],"company":[{"id":"solti","kind":"company","name":"SOLTI Cancer Research Group","route":"/companies/solti/"}]}}